Literature DB >> 7470171

Plasmapheresis in systemic lupus erythematosus: a cautionary note.

R Schlansky, R J DeHoratius, T Pincus, K S Tung.   

Abstract

Plasmapheresis was used as the sole treatment modality in 4 patients with systemic lupus erythematosus. The presence of circulating immune complexes in this group of patients was not predictive of response to plasmapheresis. Lymphocytotoxic antibody levels fell in 3 of the 4 patients, and no consistent changes in T lymphocytes, T lymphocyte subsets, complement, or immunoglobulin levels were observed. Followup during the subsequent 6 months showed deterioration in clinical and laboratory parameters in all 4 patients, and the protocol was discontinued. Plasmapheresis without concomitant therapy may be detrimental to certain patients with systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7470171     DOI: 10.1002/art.1780240108

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  4 in total

1.  Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor.

Authors:  G Sturfelt; S Lenhoff; B Sallerfors; O Nived; L Truedsson; A G Sjöholm
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

Review 2.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

3.  Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus.

Authors:  K K Colburn; G A Gusewitch; B S Statian Pooprasert; R H Weisbart
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

Review 4.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.